Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

817.48 +13.74 (+1.71%)
Streaming Delayed Price Updated: 9:47 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About argenx SE? ↗
 
Via Benzinga
News headline image
12 Analysts Have This To Say About argenx ↗
 
Via Benzinga
News headline image
Is argenx Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth ↗
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules ↗
Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow. 
Via Chartmill
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
News headline image
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria. 
Via Chartmill
News headline image
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through. 
Via The Motley Fool
Topics Workforce
News headline image
Assessing argenx: Insights From 12 Financial Analysts ↗
 
Via Benzinga
News headline image
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy ↗
ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum. 
Via Chartmill
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of... 
Via Benzinga
News headline image
Price Over Earnings Overview: argenx ↗
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up... 
Via Benzinga
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy ↗
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability. 
Via Chartmill
News headline image
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
3 Healthcare Pathbreakers With Long-Term Tailwinds ↗
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines. 
Via MarketBeat
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win ↗
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.